[HTML][HTML] Sacituzumab govitecan in metastatic triple-negative breast cancer

…, F Dalenc, P Aftimos, F Lynce, S Diab… - New England journal …, 2021 - Mass Medical Soc
Background Patients with metastatic triple-negative breast cancer have a poor prognosis.
Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the …

Clostridium difficile infection in horses: a review

SS Diab, G Songer, FA Uzal - Veterinary microbiology, 2013 - Elsevier
Clostridium difficile is considered one of the most important causes of diarrhea and enterocolitis
in horses. Foals and adult horses are equally susceptible to the infection. The highly …

Tumor characteristics and clinical outcome of elderly women with breast cancer

SG Diab, RM Elledge, GM Clark - JNCI: Journal of the National …, 2000 - academic.oup.com
S-phase fraction (the fraction of tumor cells in S phase of the cell cycle) and DNA ploidy were
evaluated by flow cytometry (15,16). S-… , such as hypertension and diabetes, which in turn …

[PDF][PDF] MAP kinase-interacting kinases—emerging targets against cancer

S Diab, M Kumarasiri, M Yu, T Teo, C Proud, R Milne… - Chemistry & biology, 2014 - cell.com
… Given the complexity of cancer, a combination of Mnk inhibitor with other critical pathways
targeting agent(s) might be considered as an additional therapeutic approach. However, a …

[HTML][HTML] Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular …

…, L Gore, DR Camidge, S Diab, S Leong… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs),
pharmacodynamics, and preliminary anticancer activity of ramucirumab (IMC-1121B), a fully …

[HTML][HTML] Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the …

…, LA Mina, HS Rugo, KH Lee, A Gonçalves, S Diab… - Annals of …, 2020 - Elsevier
Background In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy
(hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P < 0.0001) and …

CDK7 inhibitors in cancer therapy: the sweet smell of success?

S Diab, M Yu, S Wang - Journal of medicinal chemistry, 2020 - ACS Publications
… have confirmed the role of CDK7 in phosphorylating CDK4/6 to phosphorylate the
retinoblastoma (Rb) protein for G1 progression, CDK2 to promote the progression from the G1 to S

Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas

SG Diab, GM Clark, CK Osborne, A Libby… - Journal of clinical …, 1999 - ascopubs.org
PURPOSE: To comprehensively characterize the clinical and biologic features of tubular and
mucinous carcinomas in a large cohort of patients and to relate this to clinical outcome and …

[PDF][PDF] Exome sequencing identifies FUS mutations as a cause of essential tremor

…, D Spiegelman, A Noreau, S Diab… - The American Journal of …, 2012 - cell.com
… A detailed version of this study’s methodology is supplied in the Supplemental Data,
available online. In brief, one ET-affected family, FET1, was chosen for study (Figure S1). During …

Mutations in DCC Cause Congenital Mirror Movements

…, P Hince, S Diab, N Sharafaddinzadeh, S Chouinard… - Science, 2010 - science.org
… DCC is a receptor for netrin-1, a diffusible extracellular protein that helps guide axons of
the developing nervous system across the body’s midline (3). The fourth and fifth fibronectin …